InvestSMART

Neurotech International Limited (ASX: NTI) - Announcements

- Current share price for NTI : $0.017

ASX company news and announcements for Neurotech International Limited (NTI) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neurotech International Limited (NTI) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neurotech International Limited (NTI), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neurotech International Limited (NTI)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$22 Secondary Trading Notice 21 Jul 2026 4:43PM $0.017 $0.017 fallen by 0%
$22 Application for quotation of securities - NTI 21 Jul 2026 4:37PM $0.017 $0.017 fallen by 0%
$22 Neurotech secures $3.15 million R&D tax incentive loan 15 Jul 2026 12:11PM $0.017 $0.017 fallen by 0%
$22 US FDA clears IND for NTI164 14 Jul 2026 8:50AM $0.016 $0.017 risen by 6.25%
$22 Notification regarding unquoted securities - NTI 13 Jul 2026 7:16PM $0.016 $0.017 risen by 6.25%
$22 Proposed issue of securities - NTI 13 Jul 2026 9:32AM $0.017 $0.017 fallen by 0%
$22 NTI secures Notices of Allowance for US patent applications 2 Jul 2026 9:35AM $0.014 $0.017 risen by 21.43%
$22 Notification of cessation of securities - NTI 29 Jun 2026 4:39PM $0.014 $0.017 risen by 21.43%
$22 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 9:42AM $0.012 $0.017 risen by 41.67%
$22 Change of Director's Interest Notice 28 Apr 2026 3:20PM $0.013 $0.017 risen by 30.77%
$22 Notification of cessation of securities - NTI 28 Apr 2026 3:18PM $0.013 $0.017 risen by 30.77%
$22 Ceasing to be a substantial holder 23 Apr 2026 6:40PM $0.012 $0.017 risen by 41.67%
$22 Neurotech to present at Ignite Investment Summit Hong Kong 13 Apr 2026 9:19AM $0.014 $0.017 risen by 21.43%
$22 Change of Director's Interest Notice x 4 31 Mar 2026 6:17PM $0.013 $0.017 risen by 30.77%
$22 Secondary Trading Notice 30 Mar 2026 6:44PM $0.013 $0.017 risen by 30.77%
$22 Application for quotation of securities - NTI 30 Mar 2026 6:37PM $0.013 $0.017 risen by 30.77%
$22 Neurotech to present at NWR Virtual Healthcare Conference 23 Mar 2026 9:28AM $0.010 $0.017 risen by 70%
$22 Corporate Presentation 18 Mar 2026 9:33AM $0.012 $0.017 risen by 41.67%
$22 NTI initiates First Clinical Site for Phase 3 ASD Trial 17 Mar 2026 9:32AM $0.011 $0.017 risen by 54.55%
$22 Results of General Meeting 12 Mar 2026 2:10PM $0.012 $0.017 risen by 47.83%
$22 Appendix 4D & Half Year Report 26 Feb 2026 6:15PM $0.014 $0.017 risen by 21.43%
$22 Positive 90-day GLP toxicology study results in non-rodents 23 Feb 2026 9:45AM $0.014 $0.017 risen by 21.43%
$22 NTI Collaborates with University of Sydney in Rett program 18 Feb 2026 9:38AM $0.014 $0.017 risen by 21.43%
$22 Notice of General Meeting/Proxy Form 10 Feb 2026 4:10PM $0.014 $0.017 risen by 21.43%
$22 Approval received for NTI164 Phase 3 Clinical Study in ASD 2 Feb 2026 9:36AM $0.013 $0.017 risen by 30.77%

1 - 25 of 677 results

Page 1 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.